BioSpace News Archive

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced the online publication in Cancer Cell of Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center randomized phase 3 trial.

Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut allergy which is designed to be safe, effective and convenient, today announces that it has received a green light for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA).

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 15 new employees.

The All of Us Research Program’s Journey mobile exhibit is traveling across the country to engage communities that have been historically underrepresented in medical research.

Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, announced that it has granted an inducement stock option to purchase 134,550 shares of its common stock to Darrell Taylor, its new Senior Vice President, General Counsel and Chief Compliance Officer.

Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, announced the appointment of Bart Henderson as Chief Executive Officer.

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the Cowen 42nd Annual Healthcare Conference.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the initiation of the EQUATOR study, a pivotal Phase 3 clinical study of itolizumab in patients with acute graft-versus-host disease (aGVHD).

Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, announced that it will attend the 34th Annual Roth Conference, being held on March 13-15, 2022 at The Ritz Carlton, Laguna Niguel in Dana Point, California.

Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that real world data on Endari®, the company’s prescription-grade L-glutamine oral powder for the treatment of sickle cell disease, has been accepted for an e-poster at the 62nd Annual Meeting of the British Society for Haematology.